PHOTOBIOMODULATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Photobiomodulation Market Size and Trends

The global photobiomodulation market is estimated to be valued a USD 230.3 Mn in 2024 and is expected to reach USD 455.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031. The rising prevalence of chronic diseases and increasing adoption of non-invasive procedures are expected to drive demand over the forecast period.

Discover market dynamics shaping the industry: Request sample copy

The market is witnessing positive trends with the growing application scope for photobiomodulation therapy. It is increasingly being used in therapeutic areas like wound healing, pain management, and aesthetic treatment. Furthermore, clinical validation and approval for new indications will expand the market potential. Portable and affordable devices are also gaining interest among both patients and healthcare providers.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights by Application- Application in Pain Management Leads Due to Non-Invasive Light Therapy

 In terms of application, pain management segment is estimated to contribute the highest market share of 42.1% in 2024 owing to photobiomodulation's non-invasive nature and its ability to address pain at its source. Managing pain has become increasingly important as populations age and active lifestyles lead to more injuries. Photobiomodulation allows patients to reduce their reliance on pharmaceuticals for pain relief by delivering light therapy directly to painful areas. This targets inflammation and accelerates the body's natural healing processes.

Insights by Wavelength - Effective Deep Tissue Healing Drives Infrared Light Segment’s Dominance

In terms of wavelength, infrared light segment is estimated to contribute the highest share of the photobiomodulation market of 42.3% in 2024 due to its deep tissue penetration and effectiveness for dermal applications. Infrared wavelengths allow photobiomodulation to target pain and injuries below the skin's surface by transmitting light energy through layers of fat, muscle, and connective tissue. This makes infrared light ideal for addressing joint problems, muscle strains, and nerve pain that originate deeper in soft tissue. 

Insights by Type of Device - Precision-Driven Innovation Drives Demand for Low-level Laser Therapy

 In terms of type of device, low-level laser therapy (LLLT) devices segment is estimated to contribute the highest market share of 45.1% in 2024 due to their precision, control, and versatility. LLLT devices are technological marvels offering both quantitative and qualitative capabilities superior to other light sources. Laser diodes and sophisticated optics allow for milliwatt output levels regulated to microwatts, precisely controlling how much light energy is delivered. Computerized features and attachments enable customized, patterned illumination of targeted areas.

Regional Insights

To learn more about this report, Request sample copy

Regional Analysis:

Dominating Region: North America

North America dominates the photobiomodulation market with an estimated share of 35.2% in 2024. This can be attributed to factors such as a strong presence of key market players, favorable reimbursement policies, and rising awareness about photobiomodulation therapies. The region is home to many innovators and early adopters of photobiomodulation technologies.

Fastest-Growing Region: Asia Pacific

The Asia Pacific market exhibits the fastest growth, led by China, India, and other emerging Asian countries. Governments in the region are increasingly focusing on improving access to advanced healthcare through strategic policy reforms. This is encouraging the widespread adoption of photobiomodulation across applications such as wound healing and pain management.

Photobiomodulation Market Outlook for Key Countries

Dominant Market with High Adoption Rates in the U.S.

The U.S. leads the photobiomodulation market due to the high prevalence of chronic pain and increasing acceptance of non-invasive therapies. In April 2023, according to Centers for Disease Control and Prevention, in 2021, 20.9% of U.S. adults (51.6 million) experienced chronic pain, and 6.9% (17.1 million) faced high-impact chronic pain that significantly limited daily activities, driving the demand for effective treatment options.

Healthcare Innovations in Canada

Canada photobiomodulation market is expanding as healthcare providers increasingly adopt photobiomodulation therapies. A report from the Canadian Institute for Health Information in November 2022, indicated a 20% increase in the use of photobiomodulation devices in hospitals over the past year, reflecting growing acceptance.

Technologically Advanced Market with Strong Research Focus in Japan

The Japan photobiomodulation market benefits from advanced technology and significant research investments. The Ministry of Health, Labour and Welfare reported in October 2023 that photobiomodulation therapies are being integrated into standard pain management protocols in hospitals, contributing to market growth.

Australia Leads in Arthritis Treatment and Pain Management Innovation in Australia

Australia's leading position in healthcare markets such as arthritis treatments and photobiostimulation is largely driven by the rising prevalence of arthritis. According to the Australian Bureau of Statistics, approximately 3.7 million Australians (14.5%) were living with arthritis as of December 2022. The condition is notably more common among individuals aged 45–54 years, where the prevalence reaches 16.2%, compared to just 2.5% in those aged 0–44 years.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by Global Photobiomodulation Market Players

• Established Players: Leading companies in the global photobiomodulation market focus extensively on research and development to innovate high-performance products. They invest heavily in R&D to develop new technologies and solutions. For instance, Thor Photomedicine and Aerolase Corp. invest over 15% of their annual revenue in R&D activities to deliver innovative laser therapy devices.
• Strategic Partnerships: Major players also focus on strategic alliances with OEMs and other players to strengthen their market presence. For example, THOR Photomedicine signed agreements with several medical device companies to distribute its new light therapy products globally.
• Mid-Level Players: Mid-level players in the market focus on delivering quality photobiomodulation therapy devices at affordable price points. This enables them to target price-sensitive users effectively. Companies like BioLight Technologies Ltd. and Vielight Inc. have grown significantly with their portfolio of budget-friendly laser therapy solutions.

Emerging Startups in the Global Photobiomodulation Market

Innovative Technologies: Some startups at the forefront of innovation in this market include PhotoniCare and Quantmod. PhotoniCare is developing "smart sensors" integrated in light therapy devices to monitor treatment outcomes in real-time using AI.

Quantmod is focused on portable photobiomodulation devices controlled via smartphone apps. Such advanced technologies could revolutionize light therapy delivery and self-care treatment options.

Sustainable Solutions: Companies like Healht and Viora are working on sustainable and eco-friendly light therapy solutions. Healht produces photobiomodulation devices that run on renewable energy with minimal electrical waste. Viora uses recyclable materials in manufacturing and offers product replacement programs to reduce e-waste from outdated devices.

Photobiomodulation Industry News

• In August 2024, LumiThera,, a leader in photobiomodulation (PBM) treatments for eye conditions, announced the approval of a new Category III CPT code for photobiomodulation (PBM) therapy in retinal disease, effective January 2025. This milestone is supported by the LIGHTSITE III clinical trial, which demonstrated significant vision improvements and reduced disease progression in dry age-related macular degeneration (AMD) patients using the Valeda PBM system. With over 80% patient compliance and sustained benefits observed over 21 months, this development marks a crucial step toward wider access and reimbursement for non-invasive PBM treatments.
• In January 2024, Iridex Corporation, a medical instrument manufacturing company, introduced two next-generation laser platforms, the Iridex 532 nm and Iridex 577 nm. These lasers utilize Iridex’s patented technology for laser delivery, designed to regulate photothermal effects during laser photocoagulation by allowing tissue to cool between pulses, thereby reducing or preventing potential tissue damage.
• In January 2024, PhotoMedex, a leading provider of advanced light-based therapies,entered into a strategic partnership with Zimmer Biomet, a global leader in the orthopedic medical device industry, to develop and commercialize photobiostimulation devices specifically designed for orthopedic applications

Key Takeaways from Analyst

• Rising prevalence of dermatological and musculoskeletal disorders worldwide will be a key driver boosting the demand for photobiomodulation therapies. Furthermore, increasing adoption of non-invasive procedures and growing geriatric population susceptible to various age-related conditions will propel the market forward.
• However, lack of reimbursement policies for photobiomodulation treatments especially in developing nations may impede market potential in the short-run. Moreover, high costs associated with laser and light therapy devices could restrict market growth to some extent.
• The Asia Pacific region excluding Japan is anticipated to emerge as the fastest growing regional market due to rising medical tourism, fast economic development, and improving access to healthcare in countries like China and India. North America will likely continue dominating the global market supported by advanced healthcare infrastructure and investments in research and development. Latin America and the Middle East & Africa also offer promising growth opportunities for photobiomodulation manufacturers.

Market Report Scope

Market Dynamics

Market Driver - Increasing prevalence of chronic pain and wounds

Chronic pain and non-healing wounds have become more prevalent with modern lifestyles, including prolonged sitting, stress, pollution, and unhealthy diets. These factors weaken human physiology, leaving many to endure persistent pain or slow-healing wounds for extended periods. According to the Osteoarthritis Action Alliance's January 2024 report, one in five U.S. adults have arthritis, with osteoarthritis affecting 32.5 million people. This high prevalence is expected to drive the demand for photobiostimulation therapy in the U.S. during the forecast period.

Market Challenge - High cost of photobiomodulation devices

One of the key challenges in the global photobiomodulation market is the high cost of photobiomodulation devices. These devices use lasers or LED lights to treat pain and various medical conditions. However, the capital cost of setting up the required laser equipment for treatment is substantial. Commonly used wavelengths such as 635nm, 670nm, and 830nm also require expensive specialized laser diodes or LED modules. Additional costs are incurred towards regular servicing and safety certifications for these systems.

Market Opportunity - Advancements in Technology and Product Innovation

The photobiomodulation market is poised to experience significant growth due to ongoing advancements in underlying technology and rising product innovation. Manufacturers are launching portable and handheld photobiomodulation devices that are more affordable and accessible for home use and small clinics. For instance, in June 2023, Lumaflex, a health tech company, launched the Lumaflex Body Pro, an U.S. FDA (Food and Drug Administration Class 2-certified red light therapy device. Popular among bodybuilders and MMA athletes, it offers advanced muscle recovery solutions.

Key Stakeholders of Market

What does Growth in the Photobiomodulation Industry mean for Different Stakeholders?

The photobiomodulation market has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

•  Application Insights (Revenue, USD Mn, 2019 - 2031)
• • Pain Management
  • Wound Healing
  • Dermatology
  • Orthopedics
  • Other Applications
•  Wavelength Insights (Revenue, USD Mn, 2019 - 2031)
• • Infrared Light
  • Red Light
  • Other Wavelengths
•  Type of Device Insights (Revenue, USD Mn, 2019 - 2031)
• • Low-Level Laser Therapy (LLLT) Devices
  • Light Emitting Diode (LED) Devices
  • Other Devices
•  End User Insights (Revenue, USD Mn, 2019 - 2031)
• • Hospitals
  • Clinics
  • Home Care Settings
  • Research Institutes
  • Others
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Alcon Inc.
  • THOR Photomedicine Ltd.
  • BioLight Technologies LLC
  • Erchonia Corporation
  • Vielight Inc.
  • Lumenis Ltd.
  • Aspen Laser Systems
  • Noveon Inc.
  • Apira Science Inc.
  • LightForce Therapy
  • Zynex Medical
  • BTL Industries
  • LaserStar Technologies
  • Meditech
  • QRS Global